中性pH值、低葡萄糖降解产物腹膜透析液的生物相容性

肾脏病与透析肾移植杂志 ›› 2011, Vol. 20 ›› Issue (6): 571-575.

中性pH值、低葡萄糖降解产物腹膜透析液的生物相容性

出版日期:2011-12-28 发布日期:2011-12-20

Review about the biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions

Online:2011-12-28 Published:2011-12-20

摘要/Abstract

摘要：

摘要传统腹膜透析液的高浓度葡萄糖、葡萄糖降解产物(glucose degradation products，GDP)、糖基化终产物(Advanced glycation end products，AGE)、低pH值等生物不相容性是影响腹膜透析疗效、导致腹膜透析技术失败的主要原因。因此研制生物相容性更好的透析液，已成为改进腹膜透析质量的重要内容。使用中性pH值、低葡萄糖降解产物（neutral pH, low-GDP，NpHLGDP）的透析液可能是延长腹膜寿命、提高治疗效果的有希望的新方法。本文主要针对NpHLGDP腹膜透析液的生物相容性，评价生物相容性的生物标志物以及可能的临床预后加以综述。

关键词: 腹膜透析液 , 生物相容性 , 葡萄糖降解产物 , 残余肾功能

Abstract:

ABSTRACT The development of peritonitis, the decline of residual kidney function, and the loss of peritoneal membrane function are central events for patients with peritoneal dialysis and affect technique survival. These are closely correlated with the poor biocompatibility of conventional peritoneal dialysis (PD) solutions containing high concentration of glucose, glucose degradation products (GDPs) coupled with the hyperosmolarity, reduced pH, and use of lactate as the buffer. Therefore, the use of neutral pH, low-GDP (NpHLGDP), bicarbonate-buffered PD solutions may represent a promising strategy to attenuate some of these adverse effects. In this article, we will highlight evidence regarding the biocompatibility of NpHLGDP PD solutions and compare the advantage and disadvantage of NpHLGDP PD solutions with traditional PD solutions, review the utility of current biomarkers in the evaluation of biocompatibility, and discuss the clinical outcome data with these solutions.

Key words: Peritoneal dialysis solutions , biocompatibility , glucose degradation products residual kidney function

马坤岭，张晓良. 中性pH值、低葡萄糖降解产物腹膜透析液的生物相容性[J]. 肾脏病与透析肾移植杂志, 2011, 20(6): 571-575.

[1]	胡臻，龚德华. 肾脏替代治疗患者残余肾功能的测量与评估[J]. 肾脏病与透析肾移植杂志, 2020, 29(2): 186-190.
[2]	周伟欣，张文君，景梦怡，等. 孤立肾的研究现状[J]. 肾脏病与透析肾移植杂志, 2019, 28(3): 272-276.
[3]	李平，刘志红. 肾癌的手术治疗及残余肾功能评估与保护[J]. 肾脏病与透析肾移植杂志, 2018, 27(4): 358-363.
[4]	王萍，周婷婷，钱凯，等. 基于残余肾功能的腹膜透析剂量评估[J]. 肾脏病与透析肾移植杂志, 2018, 27(1): 35-40.
[5]	尹飞挺\|谌璐\|孙洪芹\|等. 影响腹膜透析患者残余肾功能下降速率的因素[J]. 肾脏病与透析肾移植杂志, 2015, 24(1): 26-31.
[6]	王奕\|江薇\|刘峰\|等. 新型腹膜透析液影响患者临床预后的Meta分析[J]. 肾脏病与透析肾移植杂志, 2014, 23(6): 533-538.
[7]	周岩,王涵,周婷婷,等 . 腹膜透析联合血液透析治疗终末期肾病[J]. 肾脏病与透析肾移植杂志, 2013, 22(5): 422-426.
[8]	周岩, 季大玺. 腹膜透析和血液透析联合治疗终末期肾病:一种新的治疗模式[J]. 肾脏病与透析肾移植杂志, 2013, 22(2): 175-179.
[9]	俞雨生. 残余肾功能状态是选择腹膜透析的关键[J]. 肾脏病与透析肾移植杂志, 2011, 20(3): 255-256.
[10]	汪涛. 腹膜透析患者与残余肾功能[J]. 肾脏病与透析肾移植杂志, 2011, 20(3): 256-257.

ISSN 1006-298X CN 32-1425/R